Treatment persistence of ustekinumab and vedolizumab in IBD patients is independent of prior immunogenicity to anti-TNFs: a retrospective study.

Andreas BleslWolfgang PetritschLukas BinderStefan FürstHeimo WenzlFranziska Baumann-DurchscheinPatrizia KumpChristoph Högenauer

Published in: Scandinavian journal of gastroenterology (2022)

Immunogenicity to anti-TNFs does not influence treatment persistence of subsequent ustekinumab and vedolizumab therapy.

Keyphrases